Scale and growth STERIS is expanding with a $600 million investment in a new chemistry manufacturing, research and distribution complex in North Carolina, signaling a capacity and efficiency push. This presents cross-sell opportunities for infection prevention, lifecycle services, and advanced cleanroom or lab automation solutions to support expanded operations.

Healthcare demand durability The company reports robust recurring demand in healthcare and life sciences, with FY26 revenue around $6 billion and a global workforce of over 18,000. This resilience suggests continued need for sterilization, decontamination, and infection prevention products across hospitals, pharma manufacturing, and device production partners.

Global reach STERIS operates worldwide with more than 4,000 customer-facing professionals, providing a broad base for multi-region contracts and scalable service agreements. Sales outreach can target regional health systems, CROs, and global manufacturers seeking standardized infection prevention and compliance solutions.

Strategic partnerships The company is listed on NYSE (STE) and participates in major conferences, indicating ongoing investor and partner engagement. Leverage this visibility to propose integrated solutions bundles, including data analytics for sterilization cycles, supply chain visibility, and enhanced regulatory compliance services.

Technology enablement STERIS technology stack includes Snowflake, MongoDB, Azure DevOps, and collaboration tools, suggesting potential for data-driven service offerings, remote monitoring, predictive maintenance, and digital platforms to optimize infection prevention workflows and field service productivity.